SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

“I can retire… with peace”: Nir Zuk says Palo Alto Networks finally achieved his 20-year vision with $25B CyberArk acquisition

Intel VP: "Historically, if we were to miss milestones... we usually just gave exemptions. Saying no is a pretty powerful tool"

“We’re already living in a world where AI is attacking AI”

“In many cases the first market should not be America”

Buzz

Most popular

Daily

Weekly

1

Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program

2

“Other countries have air-defense systems, but Israel’s are better”: Arrow 3 lands in Germany as Israel pursues new mega deals

3

Could Prompt Security be SentinelOne’s lifeline as shares slide 35% this year?

4

ZIM faces pivotal vote as company weighs at least three acquisition offers

5

“I can retire… with peace”: Nir Zuk says Palo Alto Networks finally achieved his 20-year vision with $25B CyberArk acquisition

Pharmaceuticals

20 stories about Pharmaceuticals

מייקל היידן מחקר ו פיתוח טבע

Former Teva Executives Raise $60 Million for Metabolic Disorders Venture

28.10.18|Lilach Baumer

The company’s pipeline of biologic and small molecule drug candidates was acquired from Teva

מוסף רפואה מבחנה מבחנות תרופה תרופות בית חולים

China’s CMS Medical Signs Multi-Million Dollar Deal With Israeli Pharma Company Can-Fite

07.08.18|Amarelle Wenkert

New York-listed Can-Fite develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer

קאר שולץ מנכל טבע

Teva Trending Down Following Underwhelming Second Quarter Revenues

02.08.18|Dror Reich

On Thursday, the generic drugmaker announced revenues that fell slightly short of analyst consensus

ה מטה הנוכחי של טבע ב ארה"ב

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer

Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800

נאסד"ק וול סטריט

Oral Insulin Capsule Developer Oramed Raises $18 Million in Direct Offering

Jerusalem-headquartered Oramed intends to use the recent proceeds for research and development and for clinical trials

קאר שולץ מנכל טבע

Teva to Relocate U.S. Headquarters to New Jersey

08.07.18|Lilach Baumer

In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt

חדר מיון בית חולים שיבא תל השומר

Cost-Cutting at CureTech Following Cancellation of Acquisition Deal with Insight

The deal was announced in March, but intended buyer InSight backed out

קאר שולץ מנכל טבע

Goldman Sachs Sees 16% Upside in Teva Stock

26.06.18|Dror Reich

Following a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price

נאסד"ק וול סטריט

Liver Treatment Company Galmed Looking to Raise $75 Million in Public Offering

20.06.18|Dror Reich

Galmed listed on Nasdaq in 2014. The company's stock jumped around 125% over the past two weeks following a successful study

MediWound’s Pineapple-Based Burn Treatment to Treat Mustard Gas Burns

31.05.18|Dror Reich

The Nasdaq-listed, Israeli based company received the FDA’s approval to expand the use of flagship burn treatment NexoBrid to those suffering from Sulfur Mustard injuries

Ferring Per Falk

At Swiss Pharma Company, Women’s Health Gets Personal

23.05.18|Lilach Baumer

Ferring Pharmaceuticals recently launched a personalized fertility treatment that supports its hormone therapy with a dosage calculation app

וורן באפט אסיפת בעלי המניות מאי 2018

Berkshire Hathaway Solidified its Teva Position in 2018 First Quarter

16.05.18|Lilach Baumer

According to a Tuesday filing, Berkshire Hathaway more than doubled its Teva stake during the first quarter of 2018

בריאות דיגיטלית מדעי החיים רפואה טיפול 1

Israel’s Life Sciences Industry Is Dominated by Small Scale Startups

14.05.18|Lilach Baumer

65% of all Israel-based life sciences companies employ 10 people or less, according to a new report

מטה טבע פתח תקווה

Building on Strong First Quarter, Teva Raises 2018 Outlook

03.05.18|Lilach Baumer and Dror Reich

The company reported a 10% decrease in revenues compared to 2017, largely due to North American Copaxone troubles, but beat analyst expectations

Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange

29.04.18|Racheli Bindman

Dually listed on Nasdaq and TASE, Opko first submitted a request to delist from the TASE in early April

מוסף 16.5 הון אנושי סול ג'יי בארר Sol J. Barer

Three Board Members to Leave Distraught Drugmaker Teva

26.04.18|Lilach Baumer and Dror Reich

Teva, one of the world's largest generic drugmakers, has faced increasing difficulties the past two years

מנכ"ל ג'נרל אלקטריק ג'ון פלאנרו

General Electric, Roche Weigh Israel, Finland as Possible Locations for Joint Research Operation

22.04.18|Yoav Stoler

The World Economic Forum’s global competitiveness report for 2017-2018 ranked Israel third in innovation and Finland fourth

קנאביס קנביס רפואי מריחואנה יצוא

Israeli Cannabis Company Signs Deal With Unnamed Canadian Company Worth “Hundreds of Millions of Shekels”

Together Pharma announced the deal days before Israel’s cannabis export reform was blocked yet again by a ministerial dispute

אינטק פארמה ממנה את ד"ר ג'ון קוזריץ' לתפקיד יו"ר החברה

Intec Pharma Announces Public Offering of Ordinary Shares on Nasdaq

11.04.18|Dror Reich

The pharmaceutical company is currently listed on Nasdaq and the Tel Aviv Stock Exchange. Investment firm Oppenheimer & Co.will serve as the sole book-running manager

Teva and Rimsa Settle Contested $2.3-Billion Acquisition Deal Out of Court

10.04.18|Dror Reich

Teva acquired the Mexican plant in 2016 but shut it down immediately, citing discrepancies between Rimsa's regulatory filing and the actual assets, and filed a suit against the former owners

Previous Articles More Articles